Navigation Links
Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
Date:4/12/2011

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA.  The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011.  Jim Scopa from MPM will join the Conatus Board of Directors.

Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.

"We've watched the progress at Conatus and believe that CTS-1027 could make a significant difference in the treatment of HCV infection.  MPM also expects to provide other resources, both strategic and clinical, to assist the management team in the execution of its business plan", said Jim Scopa, Managing Director of MPM Capital.

"The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010," said Steven J. Mento, Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
2. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
3. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
10. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
11. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Department of,Justice announced today that it will not ... (CRC) to develop and publicize model contract language,for ... Department said,the language is not likely to be ... in contract negotiations, potentially reducing costs,and shortening the ...
Cached Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Hepatitis ... C Relapsers and Nonresponders, KENILWORTH, N.J., Nov. 15 ... European Commission on,October 30 approved 48-week standard-dose PEGINTRON(TM) (peginterferon,alfa- 2b, ... mg,daily) combination therapy for retreating adult patients with chronic,hepatitis C ...
... largely on children entering school ready to learn, and ... children for school entry. A new study finds that ... for school, suggesting that intervention could help boost readiness ... Laval University, the University of Montreal, and the University ...
... some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay News) -- ... allow certain drugs to be sold by pharmacists without ... to arguments for and against the proposal by representatives ... at the day,s end, the FDA officials said they ...
... Response Genetics, Inc.,(Nasdaq: RGDX ) a company ... cancer, today announced its consolidated financial results for,the ... September 30, 2007. "The third quarter of ... physician and investment communities," said Kathleen Danenberg,President and ...
... Dragon Pharmaceutical Inc.,(TSX: DDD; OTC BB: DRUG; BBSE: ... and nine months ended September 30, 2007, showing ... antibiotic business. Meanwhile,the Company also announced the sale ... a separate press release. Highlights for the ...
... Holdings, Inc. (the,"Company") today announced its operating results for ... Three Months Ended September 30, 2007 Net Revenues ... for the three months,ended September 30, 2007, increased by ... Patient days increased by 289 during the 2007 period.,During ...
Cached Medicine News:Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Environment plays key role in children's readiness for school 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 2Health News:Response Genetics Reports Third Quarter 2007 Financial Results 3Health News:Response Genetics Reports Third Quarter 2007 Financial Results 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 5Health News:Response Genetics Reports Third Quarter 2007 Financial Results 6Health News:Response Genetics Reports Third Quarter 2007 Financial Results 7Health News:Response Genetics Reports Third Quarter 2007 Financial Results 8Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 2Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 3Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 2Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 3Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 5Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 6Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 7Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 8Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 9Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 10Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 11Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 12Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 13Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 14Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 15
Pipetman 8X200 Multichannel Pipette is an eight-channel, fully adjustable, air-displacement pipette having a useful volume range from 20 L to 200 L. Robustwith the usual Gilson qualities this pipette...
Inquire...
... is precision, ergonomics, and value! , ... soft non-slip, contoured handle , Finer control ... action , Stress-free tip ejection with long, ... easy decontamination and sterilization without the need ...
... Lightest Pipettor , , The Shortyavailable with ... of how our face-to-face relationship with the scientific ... that make pipetting easier and more effective., ... pipettors., Gets you closer to the working ...
Medicine Products: